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ABSTRACT
Introduction: With the development of
magnetic resonance imaging (MRI) and
publications about radiologically isolated
syndrome (RIS), a lot of patients are referred to
multiple sclerosis (MS) tertiary centers to
confirm diagnosis of RIS or MS when brain T2
abnormalities are identified, whatever their
characteristics. We evaluate prospectively the
occurrence of RIS or MS and sensitivity,
specificity and predictive value of McDonald
criteria in diagnosis for patients presenting with
incidental brain MRI T2 lesions.
Methods: The authors ran standardized
procedures on 220 consecutive patients
addressed by general practitioners or
neurologists to confirm RIS or MS diagnosis on
brain MRI and give a therapeutic advice. All
patients underwent neurological tests,
extensive blood screening, cerebrospinal fluid
(CSF) examination, visual evoked potential
(VEP) and follow-up MRI after 3, 6, 12 and
24 months to consider dissemination in time
and space.
Results: Patient characteristics were: 165
women and 55 men, mean age: 42.7 years old
(23–59). The major symptom motivating MRI
was headaches (39%), sensitive atypical
manifestations or pain (12%), mood disorders
(10%), transient visual symptoms (9%), fatigue
(8%), hormonal screening (6%), vertigo (6%),
cranial trauma (5%), and dummy run for
clinical study (5%). After a structured analysis
of T2 lesions, the suspected diagnosis was:
inflammatory disease 45%, vascular 33%, non-
pathological 19%, genetic 2%, and metabolic
1%. Extensive screening confirmed the
proposed diagnosis in 97% of cases. Among all
the 220 proposed RIS patients, only 35.4%
fulfilled the 2010 McDonald criteria, and 8%
can be categorized as RIS. Dissemination in time
criteria was present for 82.7% of MS patients
and 36% of RIS patients but none of the
vascular or non-pathological T2 abnormalities.
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Conclusion: Even if RIS was initially suspected
on MRI, only a third of the patients had an
inflammatory disease. Most of the patients had
either non-specific T2 lesions or a non-
inflammatory disease. Others were initially
well categorized but had experienced clinical
symptoms that could possibly be considered as
a first clinical event. Overdiagnosis of MS can
lead to propose an inappropriate disease-
modifying therapy.
Keywords: Brain MRI; Clinically isolated
syndrome; Incidentaloma; Multiple sclerosis;
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INTRODUCTION
With the development of magnetic resonance
imaging (MRI), a lot of patients are addressed to
neurologists to confirm diagnosis of multiple
sclerosis (MS) when brain T2 abnormalities are
found, whatever their characteristics, even if
white matter abnormalities are non-specific.
Most of the time, the patient is presented with
a radiological report notifying clearly the
diagnosis of MS. A lot of non-specialized
radiologists are not specifically aware of the
clinico-radiological diagnosis leading to MS
diagnosis. Diagnosis of MS is based on
demonstrating dissemination in space (DS)
and time on MRI and excluding other
neurological disorders that can clinically and
radiologically mimic MS [1]. The brain MRI
motive has to be a seminal event, acute or
progressive, suggestive of an inflammatory
disease. When the patient suffers from
suggestive MS symptoms, clinico-radiological
criteria are helpful to diagnose a clinically
isolated syndrome. McDonald criteria have
been applied in clinical practice with good
specificity for MRI criteria with two updates
since the original publication but may require
systematic screening (visual evoked potential,
blood and cerebrospinal fluid analysis) [1–6].
Other criteria for diagnosis of MS have been
recently proposed but are not yet validated [7].
Eventually, a lot of patients diagnosed with
potential MS are not diagnosed after a second
screening [8, 9].
For patients with non-typical MS symptoms,
a systematic review of brain and spinal MRI is
the major step to establish the diagnosis of a
demyelinating disease. Recognition of MRI red
flags, as defined by the European MAGNIMS
(Magnetic Resonance Network in Multiple
Sclerosis), improves diagnostic accuracy [10,
11].
The limited specificity of incidental non-
specific white matter abnormalities that are
revealed by MRI may increase the number of
misdiagnosis [10]. Even prior to the
introduction of radiologically isolated
syndrome (RIS) criteria, longitudinal clinical
data from individuals with incidentally
identified T2 lesions suggestive of multiple
sclerosis (MS) were described. Healthy
individuals who do not exhibit signs of
neurological dysfunction commonly have
brain MRI studies performed for a reason other
than an evaluation for MS that reveals
unexpected anomalies highly suggestive of
demyelinating plaques given their size,
location, and morphology. These healthy
subjects lack symptomatology suggestive of MS
and fulfill formal criteria for RIS, a recently
described MS subtype that expands upon the
phenotype of at-risk individuals for future
demyelinating events. A formal description of
RIS was first introduced in 2009 by Okuda et al.
[12], to define this relevant cohort of
individuals who are at risk for future
demyelinating events.
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The authors describe here a prospective
study consisting of the evaluation in clinical
practice of a step-by-step procedure in patients
presenting with non-specific symptoms and
brain T2 hyperintensities, initially diagnosed
as RIS or MS.
METHODS
From 2009 to 2012, the authors ran
standardized procedures on 220 consecutive
patients referred to their MS center by general
practitioners (GP) or neurologists for specialized
advice concerning suspected MS on brain MRI.
Brain MRI was performed by the GP for non-
specific symptoms (such as headaches, atypical
sensitive symptoms, blurred vision, and mood
disorders).
Classification of the T2 Hyperintensities
Clinical and neurological data were reviewed
with the patient and the brain MRI was
analyzed by two physicians (neuroradiologists:
LM, SC or 3 neurologists: CL, AC, MC) with a
standardized procedure considering shape, size,
number and location of T2 and T1
abnormalities on sequences with and without
gadolinium (Fig. 1). Potential chronic
inflammatory disease was retained if brain T2
hypersignals were[3 mm, ovoid and then,
Barkhof and Tintore criteria were applied [2].
If more than 3 criteria were present, RIS or MS
was suspected and DS was documented. If
hyperintensities were suggestive but with [3
DS criteria, inflammatory disease involving
central nervous system was suspected.
After this first step, the patients were
categorized by the neurologist into a disease
group with data suggestive or not of an
inflammatory process. If not, another
diagnosis was proposed: ischemic vascular
disease, metabolic, genetic or non-
pathological. Because patients were initially
assessed for a radiological suspicion of MS, all
available MRI criteria applicable were applied,
irrespective of what the neurologist’s suspected
diagnosis was [2, 4, 7, 13, 14].
Extensive Screening to Confirm the No
Better Explanation Concept
As they want to have an answer for their
diagnosis, all patients asked and agreed to
undergo neurological tests, and extensive
blood screening, including a complete blood
count, erythrocyte sedimentation rate, serum
cryoglobulins, total serum gamma globulins,
serum protein immunoelectrophoresis,
C-reactive protein, complement factors,
angiotensin conversion enzyme, antinuclear
antibodies, antinative DNA, antiphospholipid/
anticardiolipin antibodies, rheumatoid factor,
antiprothrombinase, HIV, herpes simplex virus,
varicella-zoster virus, hepatitis C and B, syphilis,
cytomegalovirus, and Epstein–Barr virus
serological tests. All patients had a
cerebrospinal fluid (CSF) analysis with cell
count, protein level and an oligoclonal band
(OCB) evaluation by isoelectrofocusing method.
Detection of an OCB was considered as positive
if more than 1 band that was not detected in the
serum was present in the CSF.
At recruitment, patients had a VEP and a
follow-up brain MRI was programmed with and
without gadolinium at 3, 6 and 12 months to
consider dissemination in time (DT) and DS.
The MRI follow-up was standardized with Axial
T1 3D: TE = 1.7; TR = 7.9; NEX = 2; FOV:
260 9 195 mm; 1.6 mm with 0.8 mm overlap;
256 x 192; 152 slices; Axial T2/DP (FSE double
e´cho): TR = 5,000; TE = 8.0 et TE = 103.9;
NEX = 2; FOV: 240 9 180 mm; 2.0 mm;
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256 9 192; 64 slices; Axial Flair (FSE IR):
TE = 157.5; TR = 10004; TI = 2,200; NEX = 1;
FOV: 240 9 240 mm; 4.0 mm; 256 9 192; 28
slices; Gadolinium injection 0.1 ml/kg; Axial
T1 post-Gd (FSE-XL): TR = 480; TE = 7.3;
NEX = 4; FOV: 240 9 180 mm; 2.0 mm;
256 9 192; 64 slices.
All charts were reviewed at 2 years to confirm
the final diagnosis, if possible.
Diagnosis Proposal and Follow-up
After a review of the patients’ personal history,
if symptoms suggestive of an inflammatory
Patients with suspected RIS
(N=220)
Step by step analysis of brain MRI
Clinical data analysis: medical history, neurological examination























CSF=cerebrospinal fluid, MS=multiple sclerosis, VEP=visual evoked potential
Fig. 1 Methodical process of ﬁles from radiologically isolated syndrome suspected patients
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disease were found independently of the
present MRI motive and MRI criteria of DS
and DT were fulfilled, the patient was diagnosed
with MS. Patients with possible RIS according to
DS criteria but with a history of clinical
symptom compatible with a first clinical event
were classified as clinically isolated syndrome
(CIS).
For the other recruited patients with non-
specific symptoms, a diagnosis was finally
proposed on the combination of clinical,
laboratory and radiological data.
Compliance with Ethics
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was not
required because all screenings were included
in the standard clinical practice. The analysis in
this article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Patient characteristics were: 165 women and 55
men, mean age: 42.7 years old (23–59). Patients
were categorized as to whether they had
symptoms and signs possibly related to T2
hypersignals (paraesthesia, vertigo, gait
control), or unlikely to be specifically related
to demyelination (isolated fatigue, headaches,
trauma, endocrinopathy). After an extensive
discussion, typical symptoms of
demyelination, either optic neuritis or
myelitis, evoking a CIS were found in 22% of
patients with T2 hypersignals suggestive of RIS.
These symptoms were not the MRI motive but
the patient was then excluded.
The major symptom motivating brain MRI
was headaches (39%), sensitive atypical
manifestations (12%), mood disorders (10%),
transient visual symptoms (9%), fatigue (8%),
hormonal screening (6%), vertigo (6%), cranial
trauma (5%), dummy run for clinical study (5%)
(Table 1).
After a structured analysis of T2
hyperintensities, the suspected diagnosis was:
inflammatory 45%, vascular 33%, non-
pathological 19%, genetic 2%, and metabolic
1%. Extensive screening confirmed the
proposed diagnosis in 97% of cases. From the
6- and 12-month visits, diagnosis was
confirmed and only three cases remained
unresolved. Among the 220 patients, only 78
(35.4%) fulfilled the 2010 McDonald criteria,
and 18 (8%) were categorized as RIS (Table 2).
DS with MS/MRI criteria applied to the first
brain MRI were fulfilled in 85% of MS, for 34.6%
of the vascular patients, and for 0 of the non-
specific hyperT2 (Table 3). 38% of patients
Table 1 Repartition of suspected radiologically isolated
syndrome patients
MRI motive N (%) Clinical history
(%)




Mood disorders 22 (10) 3
Visual 20 (9) 11
Fatigue 17 (8) 1
Hormonal screening 13 (6) 2
Vertigo 13 (6) 2
Trauma 11 (5) 1.5
Dummy run 11 (5) 1.5
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underwent initial spinal MRI. Among those
who had T2 hyper intensities compatible with
MS, 33% of them had spinal T2 lesions.
Regarding the patients who had a final
diagnosis of demyelinating disease, all MS/
MRI criteria have the same sensibility
(Table 2) [2, 13]. The association of 2 DS
criteria, a positive CSF and DT on MRI was
also sensitive and specific. None of the
patients with vascular diseases or non-
pathological T2 hypersignals had MRI criteria
and a positive CSF. DT criteria were present for
82.7% of MS patients and 36% of RIS patients
but none of the vascular or non-pathological
T2 abnormalities.
At 6 months, 35.4% of patients had finally
been diagnosed as inflammatory disease with
DT and DS. On the 24-month visit, diagnosis
was confirmed and only three cases remained
unresolved. For cases other than RIS or MS,
diagnosis was confirmed with the paraclinical
screening and identification of risk factors such
as cardiovascular risks, metabolic abnormalities,
and genetic diagnosis (one case of fragile
X-associated tremor/ataxia syndrome). The
2-year diagnostic distribution was: RIS 8%, MS
35%, other inflammatory diseases 2%, ischemic
vascular disease 17%, non-pathological 31%,
genetic 1%, and unknown 4%.
DISCUSSION
Brain MRI is the most sensitive paraclinical
diagnostic test for MS, but white matter
abnormalities are also known to be present in
many other circumstances [1, 14–16]. They
have been reported in 40–95% of patients with
other neurological diseases [8–10] and even in
44% of elderly asymptomatic patients [13].
Failure to consider the aspect of T2
hypersignals can induce misdiagnosis in some
patients fulfilling the criteria of DT and DS. In
these cases, proposing specific treatments that
are available now can be risky.
Among our 220 suspected MS patients, 43%
were diagnosed with demyelinating disease and
22% with clinical MS, due to history of
symptoms suggestive of a clinical event, acute
or progressive. With an extensive questionnaire,
neurologists can detect previous neurological
event that patients failed to report. This
contrasts with another study where 11% of
104 patients had suspected MS based on MRI
[17]. Recently, the PEDIAS study revealed that
44% of patients with a typical CIS had a
neurological history suggestive of a previous
demyelinating event [18].
Other published studies showed that in the
vast majority of patients who were referred with
Table 2 Comparison between the suspected and ﬁnal diagnosis
Suspected diagnosis N (%) Relevant Clinical history Final diagnosis
Inﬂammatory 99 (45%) 49 (22%) RIS. 18 (8%)
MS. 78 (35%)
Other inﬂammatory diseases. 4 (2%)
Vasculopathy 73 (33%) 22 (10%) 37 (17%)
Non-pathological 42 (19%) – 68 (31%)
Genetic or metabolic 6 (3%) 4 (2%) 2 (1%)
9 (4%) patients had unexplained T2 abnormalities after 2 years of follow-up
MS multiple sclerosis, RIS radiologically isolated syndrome
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suspected demyelinating disease, but in whom
no diagnosis could be made at the time of
referral, no neurological diagnosis was made
during an average follow-up of 7 years [8, 9].
Finally, diagnostic uncertainty remains for a
significant number of patients. For instance, the
manifestations of a patient with non-specific,
multifocal symptoms not typical of a CIS may
still be wrongly diagnosed as possible MS.
Correspondingly, potentially confirmatory
MRI and other test results may be normal or
nonspecifically abnormal. In these cases,
definite diagnosis is not possible and follow-up
is required.
In our cohort, the majority of T2 lesions
diagnosed on MRI as possible MS were non-
specific lesions. The medical history and clinical
analyses in MS diagnosis are very important
[19]. In most patients in whom ultimately
another diagnosis was made, it was found that
at initial clinical presentation a diagnosis of MS
could be rejected based on the association of
medical history and MRI findings. Specific
symptoms or signs pointing to the disease
were not recognized.
With the extending accessibility of MRI, RIS
is frequently overdiagnosed, either because
medical history examination reveals a
suggestive clinical event or the structured MRI
analysis rejects the diagnosis of an
inflammatory disease. Among our 220
patients, only 18 were finally diagnosed as RIS,
others having either neurological symptoms
history or T2 lesions nonsuggestive of MS.
Even if incidental brain T2 lesions are
frequent, asymptomatic patients with
hypersignals and/or gadolinium enhancement
fulfilling Barkhof/Tintore´ MRI criteria and DT
and DS are more rare [12, 20–24]. DT criteria
were present for 82.7% of MS patients and 36%
of RIS patients but none of the vascular or non-
pathological T2 abnormalities.
In these published cohorts, 80% of patients
with a RIS already fulfilled diagnostic criteria
before the seminal event. In European or North
American observational studies, the authors
have found that up to 30–45% of patients
with RIS will present clinical progression. [12,
21] The median time to clinical conversion
differs between studies being 2.3 years for the
series of French patients and 5.4 years for the
American. Most patients who develop clinical
symptoms had prior radiological progression.
The presence of asymptomatic lesions in the
Table 3 Data (% of patients) on fulﬁlled MRI criteria according to the ﬁnal diagnosis
MRI criteria (%) MS (%) Other inﬂammatory
diseases (connectivitis) (%)
Vasculopathy (%) RIS (%) Non-
pathological
(%)
3 DS criteria BARKHOF 85 20 34.6 100 0
PATY 90 50 72.3 71.4 33.3
FAZEKAS 90 20 3.9 14.3 0
SWANTON 90 40 42.3 88.6 6.7
Non-speciﬁc T2 hypersignals 5 0 7.7 28.6 86.7
2 DS criteria ? CSF abnormalities 57.8 30 0 42.3 0
DT MRI only (new T2 or gadolinium ?) 82.7 0 0 36 0
Association of 2 HS ? CSF and DT on MRI 90 30 0 44 0
DS dissemination in space, DT dissemination in time, HS hypersignal,MS relapsing remitting multiple sclerosis, CSF cerebrospinal spinal
ﬂuid
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cervical cord provides an increased risk of
progression, either to relapsing or to
progressive MS.
In longitudinal studies, it has been shown
that 88% of patients with brain T2
abnormalities developed MS and even if new
lesions can be clinically silent, the ratio of MRI
activity to clinical relapse is approximately
7–10% [4, 6, 15]. Nevertheless, before the
clinical threshold, other inflammatory diseases
might always be suspected. Many inflammatory
or infectious disorders (e.g., systemic lupus
erythematosus, sarcoidosis and
neuroborreliosis) that are commonly part of
the differential diagnosis can be investigated by
blood and CSF analyses [10]. Patients with
migraine are also frequently diagnosed with T2
abnormalities and may be over diagnosed as RIS
[25–27].
When applied intentionally, MRI and
McDonald criteria are very specific and
sensitive, providing their application is limited
to MRI abnormalities suggestive of MS, after
exclusion of ‘red flags’. In this study’s cohort,
there were neither false positives nor false
negatives for other pathologies than MS.
The paraclinical screening, for which there is
no international consensus in the literature, is
not mandatory for diagnosis of MS.
Nevertheless, it can be very useful to diagnose
DS or exclude other diagnoses [28–31]. Even if
this population is clearly different from that
seen in general neurological clinics and is biased
towards diagnostic uncertainty, a lot of
investigations could be spared if the diagnostic
criteria are correctly applied.
CONCLUSION
Patients and their physicians could be more at
ease if radiological reports were not so
affirmative concerning the MS diagnosis
without considering the clinical aspects.
Nevertheless, some tests are suggestive of a
CNS inflammatory disease, reinforcing
diagnosis and bringing in another element for
prognosis, thereby guiding treatment. Given
the benefits of early treatment in MS, but also
their further implications, diagnosis as soon as
possible is certainly essential.
Despite advancements in the
characterization of RIS subjects and in the
understanding of risk factors for initial
symptom development, the natural course of
such cases and risk profiles for a seminal
neurological event, from prospectively
acquired data, remain unclear.
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